DocWire News Editors

DocwireNews

According to research presented at the 62nd ASH Annual Meeting &amp; Exposition, combining pathology reviews with targeted sequencing of seven particular genes could improve diagnosis of myelodysplastic syndromes (MDS). The study used targeted gene sequencing data to refine classification and increase agreement in diagnosis of MDS versus &ldquo;other.&rdquo;The research was conducted as part of the National MDS Study, a project of the National Heart, Lung, and Blood Institute, part of the National Institutes of Health. It involves 92 community hospitals and 29 academic centers. Together, they are working to establish a cohort of 2,000 adults who have been recently diagnosed with MDS as well as 500 adults with idiopathic cytopenia of undetermined significance. The goals are to elucidate the genetic, epigenetic, and biological factors associated with initiation and progression of MDS.The National MDS Study collects bone marrow and blood as well as information about clinical characteristics, such as:<ul>
<li>Symptoms</li>
<li>Quality of life</li>
<li>Treatments</li>
<li>Severity of illness over time</li>
</ul>Each patient undergoes local and centralized pathology review and is assigned a diagnosis:<ul>
<li>MDS</li>
<li>Myelodysplastic/myeloproliferative neoplasms</li>
<li>Acute myeloid leukemia&nbsp;with blasts &lt;30%</li>
<li>&ldquo;Other&rdquo;</li>
</ul>Central pathologists examined patients&rsquo; peripheral blood and bone marrow biopsy specimens, clinical history, complete blood count, karyotyping, fluorescence in situ hybridization, and pathology reports from local pathologists. They used the updated 2016 World Health Organization classifications to diagnose MDS. Then, with bone marrow specimens, the researchers used targeted exon sequencing of 96 genes.Analysis involved 648 individuals classified as MDS (n=212) or other (n=436). Patients diagnosed with MDS or other by both the central and the local pathologists were the &ldquo;gold standard&rdquo; (GS) (n=546). Seventy-five percent of the GS cases were used to train and validate the models, and the remaining 25% of GS cases were used to identify an optimal probability cutoff point that could be used to classifying subjects as having MDS.That model was then used on other patients, including a group who had disagreement from local and central pathologists. The process revealed seven genes that were most helpful in differentiating MDS from &ldquo;other&rdquo;:<ul>
<li>TP53</li>
<li>SF3B1</li>
<li>U2AF1</li>
<li>ASXL1</li>
<li>TET2</li>
<li>STAG2</li>
<li>SRSF2</li>
</ul>That model was then applied to the 50 patients who had disagreement from local and central pathologists, and the model accurately reassigned, with agreement, 37 of those subjects. Overall, the study found that three of 16 &ldquo;other&rdquo; cases had been misclassified as MDS by the local pathologist.When the researchers assessed the model&rsquo;s ability to predict MDS versus &ldquo;other&rdquo; for another group of 52 subjects, overall accuracy was 83%.

Jordana Jampel

Modernization and the Rising Burden of IBD: New Insights From a Global Study

Gastroenterology

FDA Approves Novel Blood Test for Alzheimer’s Detection

Dementia

Andrew Moreno

Is Plasma Mannose-Binding Lectin a Clue to Higher VTE Risk?

Latest News

National MDS Study: Targeted Sequencing of Seven Genes Can Help Reduce Misclassification

ASH Annual Meeting 2020

According to research presented at the 62nd ASH Annual Meeting &amp; Exposition, combining pathology reviews with targeted sequencing of seven particular genes could improve ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe